Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T09:54:51.088Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychedelics as Standard of Care? Many Questions Remain

Published online by Cambridge University Press:  18 November 2022

Kurt Rasmussen  and
David E. Olson Open the ORCID record for David E. Olson [Opens in a new window]
Kurt Rasmussen*
Affiliation:
Delix Therapeutics, Inc., Concord, Massachusetts 01742, USA
David E. Olson*
Affiliation:
Delix Therapeutics, Inc., Concord, Massachusetts 01742, USA Department of Chemistry, University of California, Davis, Davis, California 95616, USA Department of Biochemistry & Molecular Medicine, School of Medicine, University of California, Davis, Sacramento, California 95817, USA Center for Neuroscience, University of California, Davis, Davis, California 95618, USA
*
*Corresponding authors. Email: [email protected]; [email protected]
*Corresponding authors. Email: [email protected]; [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
Cambridge Quarterly of Healthcare Ethics , Volume 31 , Issue 4 , October 2022 , pp. 477 - 481
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Notes

1. Dos Santos, RG, Hallak, JEC. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neuroscience & Biobehavioral Reviews 2020;108:423–34CrossRefGoogle ScholarPubMed.

2. Barrett, FS, Doss, MK, Sepeda, ND, Pekear, JJ, Griffiths, RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Science Report 2020;10:2214 CrossRefGoogle ScholarPubMed.

3. Ly C, Greb, AC, Cameron, LP, Wong, JM, Barragan, EV, Wilson, PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Reports 2018;23:3170–82Google Scholar.

4. Shao, LX, Liao, C, Gregg, I, Davoudian, PA, Savalia, NK, Delagarza, K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 2021;109:2535–44.e4CrossRefGoogle ScholarPubMed.

5. Yaden, DB, Griffiths, RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science 2020;4:568–72CrossRefGoogle ScholarPubMed.

6. Olson, DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science 2020;4:563–7CrossRefGoogle Scholar.

7. Dunlap, LE, Azinfar, A, Ly C, Cameron, LP, Viswanathan, J, Tombari, RJ, et al. Identification of psychoplastogenic N , N -dimethylaminoisotryptamine (isoDMT) analogues through structure–activity relationship studies. Journal of Medicinal Chemistry 2020;63:1142–55CrossRefGoogle ScholarPubMed.

8. Cameron, LP, Tombari, RJ, Lu, J, Pell, AJ, Hurley, ZQ, Ehinger, Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021;589:474–9CrossRefGoogle ScholarPubMed.

9. Dong, C, Ly C, Dunlap, LE, Vargas, MV, Sun, J, Hwang, I-W, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell 2021;10:2779–92.e18CrossRefGoogle Scholar.

10. Cao, D, Yu, J, Wang, H, Luo, Z, Liu, X, He, L, et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 2022;375:403–11CrossRefGoogle ScholarPubMed.

11. Yaden, DB, Earp, BD, Griffiths, RR. Ethical issues regarding non-subjective psychedelics as standard of care. Cambridge Quarterly of Healthcare Ethics 2022;31(4):464–71CrossRefGoogle Scholar.

12. Olson, DE. Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. Journal of Experimental Neuroscience 2018;12:1–4 CrossRefGoogle ScholarPubMed.

13. Nierenberg, AA, Keefe, BR, Leslie, VC, Alpert, JE, Pava, JA, Worthington, JJ, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. Journal of Clinical Psychiatry 1999;60(4):221–5CrossRefGoogle ScholarPubMed.

14. See note 11, Yaden et al. 2022.

15. See note 11, Yaden et al. 2022.

16. Carbonaro, TM, Bradstreet, MP, Barrett, FS, MacLean, KA, Jesse, R, Johnson, MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology 2016;30(12):1268–78CrossRefGoogle ScholarPubMed.

17. Carhart-Harris, R, Giribaldi, B, Watts, R, Baker-Jones, M, Murphy-Beiner, A, Murphy, R, et al. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 2021;384:1402–11CrossRefGoogle ScholarPubMed.

18. Davis, AK, Barrett, FS, May, DG, Cosimano, MP, Sepeda, ND, Johnson, MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 2021;78:481–9CrossRefGoogle Scholar.

19. Nishimura, A, Aritomi, Y, Sasai, K, Kitagawa, T, Mahableshwarkar, AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Psychiatry and Clinical Neurosciences 2018;72:64–72 CrossRefGoogle ScholarPubMed.

20. Jain, R, Mahableshwarkar, AR, Jacobsen, PL, Chen, Y, Thase, ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. International Journal of Neuropsychopharmacology 2013;16:313–21CrossRefGoogle ScholarPubMed.

21. Griffiths, RR, Richards, WA, McCann, U, Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006;187(3):268–83CrossRefGoogle ScholarPubMed.

22. Griffiths, RR, Johnson, MW, Richards, WA, Richards, BD, McCann, U, Jesse, R. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 2011;218(4):649–65CrossRefGoogle ScholarPubMed.

23. Nayak, SM, Gukasyan, N, Barrett, FS, Erowid, E, Erowid, F, Griffiths, RR. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: An analysis of online psychedelic experience reports. Pharmacopsychiatry 2021;54(5):240–5Google Scholar.

24. Elangbam, CS, Job, LE, Zadrozny, LM, Barton, JC, Yoon, LW, Gates, LD, et al. 5-hydroxytryptamine (5HT)-induced valvulopathy: Compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague–Dawley rats. Experimental and Toxicologic Pathology 2008;60(4–5):253–62.CrossRefGoogle ScholarPubMed

25. See note 11, Yaden et al. 2022.

26. Griffiths, RR, Johnson, MW, Carducci, MA, Umbricht, A, Richards, WA, Richards, BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 2016;30(12):1181–97CrossRefGoogle Scholar.

27. Griffiths, RR, Johnson, MW, Richards, WA, Richards, BD, Jesse, R, MacLean, KA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology 2018;32(1):49–69 CrossRefGoogle ScholarPubMed.

28. Griffiths, RR, Johnson, MW, Richards, WA, Richards, BD, McCann, U, Jesse, R. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 2011;218(4):649–65Google ScholarPubMed.

29. Griffiths, RR, Richards, WA, McCann, U, Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006;187(3):268–83CrossRefGoogle ScholarPubMed.

30. Corrigan, K, Haran, M, McCandliss, C, McManus, R, Cleary, S, Trant, R, et al. Psychedelic perceptions: Mental health service user attitudes to psilocybin therapy. Irish Journal of Medical Science 2021;xx:1–13. doi:10.1007/s11845-021-02668-2 Google Scholar.

31. Nour, MM, Evans, L, Carhart-Harris, RL. Psychedelics, personality and political perspectives. Journal of Psychoactive Drugs 2017;49(3):182–91CrossRefGoogle ScholarPubMed.

32. Bouso, JC, Dos Santos, RG, Alcázar-Córcoles, MÁ, Hallak, JE. Serotonergic psychedelics and personality: A systematic review of contemporary research. Neuroscience & Biobehavioral Reviews 2018;87:118–32CrossRefGoogle ScholarPubMed.

33. Forstmann, M, Sagioglou, C. Lifetime experience with (Classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. Journal of Psychopharmacology 2017;31:975–88CrossRefGoogle ScholarPubMed.

34. See note 11, Yaden et al. 2022.

35. Vargas, MV, Meyer, R, Avanes, AA, Rus, M, Olson, DE. Psychedelics and other psychoplastogens for treating mental illness. Frontiers in Psychiatry 2021;12:727117. doi:10.3389/fpsyt.2021.727117 CrossRefGoogle ScholarPubMed.

36. Available at https://www.nimh.nih.gov/health/statistics/mental-illness (last accessed 28 Feb 2022).

37. See note 35, Vargas et al. 2021, at 12.

38. See note 11, Yaden et al. 2022.

39. See note 11, Yaden et al. 2022.

40. Cuthbert, BN, Insel, TR. Toward the future of psychiatric diagnosis: The seven pillars of RDoC. BMC Medicine 2013;11:126 CrossRefGoogle ScholarPubMed.